Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from HC Wainwright

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $80.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 140.96% from the stock’s current price.

A number of other research firms have also recently issued reports on CLDX. Wolfe Research restated an “outperform” rating and issued a $51.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday. Wells Fargo & Company boosted their price objective on shares of Celldex Therapeutics from $35.00 to $37.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. Stifel Nicolaus started coverage on shares of Celldex Therapeutics in a research report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Monday, September 16th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $63.83.

Celldex Therapeutics Stock Up 1.0 %

Shares of NASDAQ:CLDX opened at $33.20 on Thursday. The stock has a market cap of $2.20 billion, a PE ratio of -11.61 and a beta of 1.56. The company’s fifty day moving average is $38.42 and its 200 day moving average is $38.43. Celldex Therapeutics has a 52 week low of $22.11 and a 52 week high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The company had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $1.13 million. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. Sell-side analysts anticipate that Celldex Therapeutics will post -2.5 EPS for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of large investors have recently modified their holdings of CLDX. UBS Group AG boosted its stake in shares of Celldex Therapeutics by 645.9% during the 4th quarter. UBS Group AG now owns 158,092 shares of the biopharmaceutical company’s stock valued at $6,270,000 after purchasing an additional 136,897 shares in the last quarter. Capstone Investment Advisors LLC bought a new stake in shares of Celldex Therapeutics during the 4th quarter valued at about $502,000. Crestline Management LP boosted its stake in shares of Celldex Therapeutics by 6.5% during the 4th quarter. Crestline Management LP now owns 67,243 shares of the biopharmaceutical company’s stock valued at $2,667,000 after purchasing an additional 4,133 shares in the last quarter. NEOS Investment Management LLC bought a new stake in shares of Celldex Therapeutics during the 4th quarter valued at about $458,000. Finally, Affinity Asset Advisors LLC boosted its stake in shares of Celldex Therapeutics by 166.7% during the 4th quarter. Affinity Asset Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $15,864,000 after purchasing an additional 250,000 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.